Attached files
| file | filename |
|---|---|
| EX-10.5B - EX-10.5B - BELLICUM PHARMACEUTICALS, INC | exhibit105b_2019equityince.htm |
| EX-32.1 - EX-32.1 - BELLICUM PHARMACEUTICALS, INC | exh321certceocfosox2020q4.htm |
| EX-31.1 - EX-31.1 - BELLICUM PHARMACEUTICALS, INC | exh311certofceocfo2020q4.htm |
| EX-21 - EX-21 - BELLICUM PHARMACEUTICALS, INC | bellicum-ex211subsidiaries.htm |
| 10-K - 10-K - BELLICUM PHARMACEUTICALS, INC | blcm-20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statements (Form S-3 Nos. 333-219020, 333-226652, and 333-232771) of Bellicum Pharmaceuticals, Inc., and
(2)Registration Statements (Form S-8 Nos. 333-201036, 333-216656, 333-218772, 333-220170, 333-223636, 333-225554, 333-231272, 333-232304, 333-232774, 333-236149, and 333-241675) pertaining to the 2006 Stock Option Plan, 2011 Stock Option Plan, 2014 Equity Incentive Plan, as amended, 2014 Employee Stock Purchase Plan, Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, and 2019 Equity Incentive Plan of Bellicum Pharmaceuticals, Inc.
of our report dated March 30, 2021, with respect to the consolidated financial statements of Bellicum Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Bellicum Pharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Houston, Texas
March 30, 2021